All In Biotech

Drug Trial Radar · NCT07897188

ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

A Randomized, Controlled, Double-Blind, Multicenter, Phase 3 Clinical Study of ASKC202 Plus Limertinib Versus Osimertinib for First-Line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 425 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

425

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 30, 2030

Study completion Nov 20, 2032

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of ASKC202 combined with limertinib as the first-line treatment for locally advanced or metastatic NSCLC

Conditions

  • EGFR Activating Mutation
  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • MET Positive

Interventions

  • ASKC202Drug

    ASKC202 tablets 200 mg QD

  • ASKC202 placeboDrug

    ASKC202 placebo tablets QD

  • osimertinib placeboDrug

    osimertinib placebo tablets QD

  • osimertinibDrug

    osimertinib tablets 80 mg QD

  • pemetrexedDrug

    pemetrexed 500 mg/m² by intravenous infusion on Day 1 of each 21-day cycle

  • cisplatin or carboplatinDrug

    cisplatin 75 mg/m² or carboplatin (AUC 5) by intravenous infusion on Day 1 of each 21-day cycle for up to 4 cycles

  • LimertinibDrug

    limertinib tablets 80 mg BID

  • limertinib placeboDrug

    limertinib placebo tablets BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) by BICRTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.